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Simon J. Harper, MD, FRCS,* and Siong-Seng Liau, MD, FRCS*Objectives: The aims of this study were to (i) identify independent pre-
dictors of survival after pancreaticoduodenectomy for ampullary cancer
and (ii) develop a prognostic model of survival.
Methods:Datawere analyzed retrospectively on 110 consecutive patients
who underwent pancreaticoduodenectomy between 2002 and 2013. Subjects
were categorized into 3 nodal subgroups as per the recently proposed nodal
subclassification: N0 (node negative), N1 (1–2 metastatic nodes), or N2 (≥3
metastatic nodes). Clinicopathological features and overall survival were
compared by Kaplan-Meier and Cox regression analyses.
Results: The overall 1-, 3-, and 5-year survival rates were 79.8%, 42.2%,
and 34.9%, respectively. The overall 1-, 3-, and 5-year survival rates for the
N0 group were 85.2%, 71.9%, and 67.4%, respectively. The 1-, 3-, 5-year
survival rates for the N1 and N2 subgroups were 84.6%, 58.4%, and 56.4%
and 80.2%, 38.8%, and 8.0%, respectively (log rank, P < 0.0001). After
performing a multivariate Cox regression analysis, vascular invasion and
lymph node ratio were the only independent predictors of survival. Hence,
a prediction model of survival was constructed based on those 2 variables.
Conclusions: Using data from a carefully selected cohort of patients, we
created a pilot prognostic model of postresectional survival. The proposed
model may help clinicians to guide treatments in the adjuvant setting.
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A denocarcinomas of the ampulla of Vater are relatively raregastrointestinal malignancies accounting for approximately
0.2% of all neoplasms arising from the gastrointestinal tract.1
They are, however, the second most frequently encountered tu-
mors among all periampullary neoplasms accounting for 7% to
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Pancreas • Volume 00, Number 00, Month 2017unlike pancreatic neoplasms that are most frequently diagnosed
in advanced stages, usually presents with symptoms of biliary
obstruction early in its development, and therefore higher resect-
ability rates (up to 82.1%) have been reported.2,4,5
The definition of what constitutes an “ampullary neoplasm”
has not been consistent in the literature, and questions have been
previously raised with regards to considering ampullary carcino-
mas as a distinct tumor entity.6 The term “periampullary tumors”
has been previously used to refer to any cancerous lesion arising
from the ampulla or its immediate vicinity, and it is amenable to
curative resection by means of pancreaticoduodenectomy.7,8 Pre-
vious reports on “periampullary tumors” have identified several
histopathological or preoperative factors (tumor histologic grade,
histological subtype, surgical resection margin involvement, pre-
operative serum bilirubin levels, and lymph node [LN] involvement)
as predictors of survival after pancreaticoduodenectomy.2,9–21 Fur-
thermore, recent evidence suggests that the currently used nodal
staging system for ampullary tumors (N0/N1) overestimates survival
in subjects with more advanced nodal disease.9,11
Previous reports, with the aforementioned limitations in def-
initions, have estimated survival after pancreaticoduodenectomy
for ampullary cancer to range from 33% to 61%,9,22 making adju-
vant therapy relevant in the context of this malignancy. However,
despite identifying predictors of survival, the selection criteria for
adjuvant therapies along with the survival benefit of such treat-
ments for ampullary cancer are not clear unlike the case of pancre-
atic cancer where such therapies have an established role in the
management algorithm.23 Identifying patients with high-risk fea-
tures would be desirable because it would guide clinicians on
offering adjuvant therapies.
The aims of this study were (i) to assess the overall survival
and identify predictors of survival after pancreaticoduodenectomy
for ampullary cancer in a high-volume hepatopancreatobiliary
unit and (ii) to develop a pilot prognostic model that can assist
clinicians in selecting patients for adjuvant therapies in the future.MATERIALS AND METHODS
Patient Population
The records of 384 patients who underwent pancreatico-
duodenectomy for periampullary lesions in our institution from
January 2002 to December 2013 were reviewed retrospectively,
with the aim of identifying those subjects who had surgery for
neoplasms arising directly from the ampulla of Vater. The study
was conducted after obtaining approval from our institution's pa-
tient safety and clinical governance review board.www.pancreasjournal.com 1
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Patient exclusion criteria were the following: metastatic or
unresectable disease at the time of surgery, indolent tumor types
(islet cell, mucinous cystadenomas), ampullary neuroendocrine
tumors, and tumors arising from anatomical locations adjacent
to the ampulla (head of pancreas, duodenum, distal common bile
duct). After applying the exclusion criteria previously mentioned,
111 patients met the study's inclusion criterion of histologically
confirmed ampullary adenocarcinoma.Pathologic Examination of the Primary Tumor
To define the origin of the resected neoplasm, we adhered to
the definition of ampullary carcinoma, as described by the Royal
College of Pathologists in the UK.24 This is defined as a tumor
grossly appearing to arise either in the ampulla of Vater (the con-
fluence of the pancreatic and common bile ducts) or the papilla of
Vater (the duodenal papilla). In cases of large tumors where the
exact origin of the tumor was difficult to extract, the tumor was
regarded as ampullary if it was centered in the ampulla or the
duodenal papilla. The tumor subtype was determined by means
of immunocytochemistry. Cytoplasmic immunoreactivity for
cytokeratin 7 and cytokeratin 20 and nuclear staining for caudal-
type homeodomain transcription factor 2 were assessed as per our
standard institutional protocol for neoplasms of hepatobiliary
origin. Data extracted from patient histology records included
the tumor size, histological subtype, degree of tumor differentiation,TABLE 1. Baseline Demographic and Histologic Characteristics of th
All Resections (n = 110)
Sex, n (%)
Male 63 (57.3)
Female 47 (42.7)
Age, median (range), y 69.2 (40–85)
Adjuvant chemotherapy, n (%)
Offered 42 (38.2)
Not offered 68 (61.8)
Tumor size, median (range), mm 25 (9–75)
T stage, n (%)
T1/T2 34 (31)
T3/T4 76 (69)
LN retrieved, median (range) 15 (2–41)
Resection margin involvement, n (%)
R1 43 (39.1)
R0 67 (60.9)
Perineural invasion, n (%)
Present 49 (44.5)
Absent 61 (55.5)
Histology subtype, n (%)
Intestinal 39 (35.4)
PB 62 (56.4)
Other/mixed 9 (8.2)
Tumor differentiation, n (%)
Well/moderate 85 (77.3)
Poor 25 (22.7)
Vascular invasion, n (%)
Present 74 (67.3)
Absent 36 (32.7)
2 www.pancreasjournal.comnumber of LNs retrieved, number of metastatic LN, vascular inva-
sion, perineural invasion, and surgical resection margin involve-
ment. The histopathology findings were described according to
the TNM staging system. The nodal stage was recalculated by 2
authors (M.F., S.I.) based on the revised nodal substaging proto-
col, proposed by Kang et al11 (LN negative [N0], 1–2 LN positive
[N1], ≥3 LN positive [N2]). Specimens with evidence of 1 mm or
smaller tumor, vascular, perineural, or nodal involvement at the
resection margin, were considered to be R1 resections, as per the
Royal College of Pathologists' guidelines on reporting histological
outcomes after major pancreatic resections.24 Perineural invasion
was defined as the presence of tumor cells in the space immediately
surrounding a nerve. Lymphovascular (or vascular) invasion was
defined as the presence of tumor within an endothelial lined or lym-
phatic space. Data were analyzed for all resections irrespective of
LN harvest. Additional analysis was performed in those resections
with 12 or more nodes retrieved.
Statistical Analysis
Details on patient follow-up were retrieved from an institu-
tional electronic database. The follow-up period was defined as
the time interval between the date of resection and that of the last
clinical interaction. Patient survival status was obtained from the
UK Cancer Registry database. Because of the difficulty in differ-
entiating cancer-related deaths from deaths from other causes, only
overall survival (ie, death from all causes) was calculated. The date
used for censoring during survival analysis was February 1, 2015.e Study Population (n = 110) and the 3 LN Subgroups
N0 (n = 35) N1 (n = 27) N2 (n = 48)
18 (51.4) 16 (59.3) 29 (60.4)
17 (48.6) 11 (40.7) 19 (39.6)
73 (43–85) 68 (40–78) 69.4 (44–84)
8 (7.3) 8 (7.3) 26 (23.6)
27 (24.5) 18 (16.4) 23 (20.9)
18 (9–65) 26 (10–75) 30 (9–60)
22 (62.3) 8 (29.6) 4 (8.3)
13 (37.7) 19 (70.4) 44 (91.7)
12 (2–30) 15 (5–24) 16 (5–41)
7 (20) 9 (33.3) 27 (56.2)
28 (80) 18 (66.7) 21 (43.8)
7 (20) 12 (44.4) 30 (72)
28 (80) 15 (55.6) 18 (38)
15 (42.8) 15 (55.6) 9 (18.8)
16 (45.7) 12 (44.4) 34 (70.8)
4 (11.5) 0 (0) 5 (10.4)
33 (94.3) 19 (70.4) 33 (68.7)
2 (5.7) 8 (29.6) 15 (31.3)
14 (40) 17 (63) 43 (89.6)
21 (60) 10 (37) 5 (10.4)
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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range. Categorical variables are presented as frequencies/percentages
(%). Comparison between categorical variableswas performed using
theχ2 or Fisher exact test. The Student t test was used for comparison
purposes between continuous variables. Survival curves were esti-
mated using the Kaplan-Meier method, and differences in survival
were ascertained using the log-rank test.
Univariate Cox regression was performed on individual
covariates to measure their marginal effect on survival. Subse-
quently, a multivariate Cox proportional hazards stepwise regres-
sion model was created to calculate the hazard ratios (HRs) and
the corresponding 95% confidence intervals (CIs) of variables in-
dependently associated with survival. The Akaike Information
Criterion (AIC) was used to select the best model for postresectional
prediction of survival. The significant covariates selected by the
stepwise regressionwere reconfirmed by a penalizedCox regression
model. Model discrimination was evaluated by calculating the
area under the receiver-operator-characteristic (ROC) curve (AUC)
calculated for ampullary cancer overall deaths at each time point
postresection. Statistical significance for all statistical calculations
was defined as P < 0.05. Statistical analysis was performed using
the R programming language (version 3.2.5, Vienna, Austria).RESULTS
Demographic and Histopathologic Results
Overall, between January 2002 and December 2013, 111 pa-
tients underwent a pancreaticoduodenectomy for ampullary
adenocarcinoma cancer. One patient was excluded from further
analysis, because the death occurred in the immediate postoper-
ative period (<30 days), leaving 110 patients as the final patientFIGURE 1. A, Nodal staging of subjects with final histology of the intest
15 (38.5%) of 39N0 resections; 15 (38.5%) of 39N1 resections, and 9 (2
were 16 (25.8%) of 62, 12 (19.4%) of 62, and 34 (54.8%) of 62, respec
patients with final histology of the intestinal and PB subtype (n = 101). Th
81.5%, 62.5%, and 60.8% versus 77.4%, 27.1%, and 15.6% for the PB
5-year survival rates of the 3 nodal subgroups for patients with final histo
© 2017 Wolters Kluwer Health, Inc. All rights reserved.population for analysis. Patient baseline demographic and histo-
pathological characteristics are summarized in Table 1. There were
no patients lost to follow-up.
The median age of the study's population was 69.2 (range,
40–85) years, and 63 (57.2%) of 110 patients were men. The me-
dian tumor diameter was 25 (range, 9–75) mm. Histological anal-
ysis revealed 34 tumors (31%) of T1 or T2 stage and 76
neoplasms (69%) of T3 or T4 stage. In 39 (35.4%) of 110 resec-
tions the tumors were of intestinal origin, in 62 cases (56.4%)
were of pancreatobiliary (PB) origin, and in 9 (8.2%)were of mixed
or other origin. In 85 subjects (77.3%), the tumors were well/mod-
erately differentiated, and in 25 patients (22.7%), they were poorly
differentiated. Perineural invasion was present in 49 (44.5%) of
110 resections, and evidence of vascular invasion was recorded
in 74 resections (67.3%). With regards to surgical resection mar-
gin involvement, 43 (39.1%) of 110 resections were deemed as
R1. In the adjuvant setting, 42 (38.2%) of 110 patients were given
chemotherapy (Table 1).Nodal Status
The median (range) number of LNs examined per specimen
was 15 (2–41). On histological analysis, a total of 75 (68.2%) of
110 specimens demonstrated evidence of LN metastases. After
restaging all resections using the newly proposed nodal classi-
fication,11 there were 35 N0 resections (31.8%), 27 N1 resections
(24.6%), and 48 N2 resections (43.6%). On univariate analysis, the
proposed advanced nodal stage (N2) was significantly associated
with the presence of aggressive tumor characteristics including
perineural invasion (P < 0.001), vascular invasion (P < 0.001),
surgical resection margin involvement (P = 0.02), PB subtype
(P = 0.006), and degree of tumor differentiation (P = 0.01).inal or PB subtype (n = 101). In the intestinal subgroup, there were
3%) of 39N2 resections. The respective figures in the PB subgroup
tively. (P = 0.191, 0.04, and <0.0001). B, Overall survival of
e 1-, 3-, and 5-year survival rates for the intestinal subgroup were
subgroup, respectively (log rank, P < 0.0001). C, The 1-, 3-, and
logy of the intestinal (n = 39) or PB subtype (n = 62).
www.pancreasjournal.com 3
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Overall, 101 (92.7%) of 110 resected neoplasms were either
of the intestinal (n = 39) or PB histological subtype (n = 62). The
median number of metastatic LN was significantly lower in neo-
plasms of the intestinal subtype compared with lesions of the
PB subtype (1.5 [0–17] and 3.0 [0–16], respectively [P = 0.04]).
Overall, in the intestinal subgroup (n = 39), there were 15 N0 re-
sections (38.5%), 15 N1 resections (38.5%), and 9 N2 resections
(23%). The respective figures in resected specimens of the PB
subtype (n = 62) were 16 N0 (25.8%), 12 N1 (19.4%), and 34
N2 (54.8%). The number of N0 resections was comparable be-
tween the 2 histological subtypes (P = 0.191); however, there
was a significant difference in the number of N1 and N2 resec-
tions between the 2 histological subgroups (P values, 0.04 and
<0.001, respectively; Fig. 1A).Postresectional Survival
The median duration of follow-up for the study's population
(n = 110) was 37.1 (2–148) months. The overall 1-, 3-, and 5-year
Kaplan-Meier estimated survival rates for the study's cohort were
79.8%, 42.2%, and 34.9%, respectively (Fig. 2A).
Overall, subjects with LNmetastases had significantly worse
median survival compared with subjects with no LN involvement
(104 months vs 22.4 months, P < 0.0001). The 1-, 3-, and 5-year
survival rates for patients without LN metastases were 85.6%,FIGURE 2. Overall postoperative survival and survival based on nodal st
1-, 3-, and 5-year survival rateswere 79.8%, 42.2%, and 34.9%, respectiv
versus no metastatic LN. The 1-, 3-, and 5-year survival rates for the LN
survival figures for those patients without LNmetastases were 85.6%, 72
5-year survival rates of the 3 LN subgroups (N0: 85.2%, 71.9%, 67.4%;
P < 0.0001).
4 www.pancreasjournal.com72.8%, and 68.5% compared with 77.0%, 27.3%, and 18.7% in
patientswith LN involvement (log rank,P< 0.0001; Fig. 2B). After
performing a subanalysis in patients with LN metastases (n = 75)
as per the proposed nodal stage (N1/N2), the 1-, 3-, and 5-year
survival rates were 81.5%, 49.4%, and 49.4% for N1 resections
compared with 75%, 19.2%, and 6.4% for N2 resections
(P < 0.001 [Fig. 2C]).
Additional survival analysis was performed on subjects be-
longing to the intestinal or PB subgroup (n = 101). The 1-, 3-,
and 5-year survival rates for node-negative resections (N0) of
the intestinal histological subtype had more favorable survival
compared with N0 resections of the PB subtype (92.9%, 86.1%,
and 86.1% vs 81.3%, 51.9%, and 41.6%, respectively;
P = 0.032; Fig. 2D). Similarly, comparison of survival between
the 2 histological subtypes for node-positive cases (N1 and N2)
differed significantly in favor of the intestinal subgroup (P = 0.04
and 0.012, respectively; Figs. 1B, C).
Multivariate Analysis and Prognostic Model
The following variables were entered initially in a Cox re-
gression model: patient sex/age at time of resection, maximum tu-
mor diameter (millimeter), tumor stage (T1/T2 or T3/T4), nodal
status, histological subtype, presence/absence of vascular or peri-
neural invasion, tumor differentiation, surgical resection margin
involvement, and adjuvant chemotherapy status. The Cox propor-
tionality assumption was validated with a χ2 test for Schoenfeldatus. A, Overall survival for the study's population (n = 110). The
ely. B, Comparison of survival between subjectswithmetastatic LN
metastases–positive patients were 77.0%, 27.3%, and 18.7%. The
.8%, and 68.5%, respectively (log rank, P < 0.0001). C, 1-, 3-, and
N1: 81.5%, 49.4%, 49.4%; N2: 75.0%, 19.2%, 6.4%; log rank,
© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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that nodal status was a significant predictor (P< 0.05). To obtain a
finer understanding of the dependence of hazard on nodal status,
we expanded it into 3 slightly different covariates: further subclas-
sification of nodal stage (N0/N1/N2), total number of metastatic
nodes present, and ratio of metastatic to retrieved nodes (lymph
node ratio [LNR]) at time of resection and included them all
in the initial full model. The estimated coefficients with 95%
CI in the initial Cox regression model are shown in Table 2.
An AIC-guided backward stepwise model selection was subse-
quently performed. The selected model with the smallest AIC
is also presented in Table 2. We found that the presence of vas-
cular invasion and high LNR were significantly associated with
worse survival. More precisely, the HR between patients with vas-
cular invasion and without was 2.57 (CI, 1.53–4.32; P < 0.001).
Every unit increase in LNR increases the hazard by a factor of
5.19 (CI, 1.20–12.5; P < 0.05). Because the results of stepwise
regressions are known to be sensitive to the order of removal of
covariates, we additionally performed an ℓ1-penalized Cox re-
gression. The entire solution path is shown as follows, whereTABLE 2. Cox Regression Analyses (Univariate/Multivariate) of Pred
Covariates
Univariate Model Multiva
HR P HR
Sex
Female 1.0 — 1.0
Male 1.07 0.78 0.99
Age, y 1.0 0.86 1.01
Adjuvant chemotherapy 1.90 0.01 0.89
Tumor size, mm 1.03 0.001 1.02
Tumor stage
T1/T2 1.0 — 1.0
T3/T4 2.62 0.001 1.00
Resection margin status
R0 1.0 — 1.0
R1 2.29 0.001 0.70
Vascular invasion
Absent 1.0 — 1.0
Present 3.44 <0.001 2.46
Perineural invasion
Absent 1.0 — 1.0
Present 2.90 0.001 1.28
Tumor differentiation
Well/moderate 1.0 — 1.0
Poor 1.63 0.07 1.50
Histology subtype
Intestinal 1.0 — 1.0
PB 2.57 0.001 1.47
Mixed/other 1.59 0.33 1.71
Nodal status
N0 1.0 — 1.0
N1 1.45 0.35 0.86
N2 5.28 <0.001 0.90
Number of metastatic LN 1.18 <0.001 1.14
LN ratio 19.8 <0.001 2.25
Numbers in bold are the independent predictors of survival after performing
© 2017 Wolters Kluwer Health, Inc. All rights reserved.the dashed line corresponds to the tuning parameter chosen via
10-fold cross-validation. The same 2 covariates, vascular invasion
and LNR, are chosen in the cross-validated penalized Cox model,
reconfirming our model selection result. A subanalysis was per-
formed in those subjects (n = 75) with 12 or more LNs retrieved,
with same 2 variables (LNR and vascular invasion) remaining as
independent predictors of survival.
The final multivariate Cox regression suggested the follow-
ing prognosis model for prediction of postresectional survival:
log hazard ratioð Þ ¼ 0:94 Ipv þ 1:6 LmetLtot þ 0:083Lmet
0
Where Ipv = 1 if vascular invasion is present and 0 otherwise. The
total number of resected and metastatic nodes is denoted by the
abbreviations Lmet and Ltot, respectively. The previously men-
tioned formula has been translated to an electronic application
for use by clinicians (Fig. 3A). The calculated AUCs at 3 and
5 years for our model were 0.85 and 0.87. The corresponding 3-
and 5-year AUC figures for the currently used nodal stagingictors of Postresectional Survival
riate Model (Full) Selected Multivariate Model
P HR 95% CI P
—
0.98
0.23
0.69
0.21
—
0.99
—
0.35
— 1.0 —
0.04 2.57 1.53–4.32 <0.001
—
0.58
—
0.21
—
0.34
0.30
—
0.75
0.87
0.05 1.09 0.99–1.19 0.09
0.40 5.19 1.20–12.5 0.03
a Cox regressional analysis.
www.pancreasjournal.com 5
FIGURE 3. A, Snapshot of electronic survival calculator. B and C, The ROC curves for ampullary cancer overall mortality at 3 and 5 years
postresection (comparison between the proposedmodel, the current nodal staging system [ie, NO/N1], and the recently proposed staging
classification [ie, N0/N1/N2]).
Feretis et al Pancreas • Volume 00, Number 00, Month 2017system (ie, NO/N1) and the proposed staging system (ie, NO/N1/N2)
were 0.69 and 0.70 and 0.75 and 0.79, respectively (Figs. 3B, C).DISCUSSION
The findings we report in this study originate from a care-
fully selected patient cohort, using strict histopathological criteria.
Our findings demonstrate that the currently used nodal staging
system (N0/N1) seems to overestimate survival in patients with
3 or more metastatic LNs. Furthermore, on the basis of the find-
ings of a stepwise Cox regression model, using 2 independent
predictors of survival (ie, LNR and vascular invasion), we have
developed a pilot prognostic model. The validity of the model
was strengthened by performing a subanalysis on subjects with
12 or more resected LNs. The model we propose is more sen-
sitive than nodal status in predicting survival as our ROC
curves demonstrate.
The 5-year survival rate in our study's population (34.9%) is
in keeping with survival figures reported by others, adding to the
validity of our patient selection criteria.2,14,18,22 It has been previ-
ously advocated that one of the reasons why ampullary carcino-
mas should be managed separately to other neoplasms arising in
the close proximity of the ampullawas the more favorable survival
figures reported after resection of ampullary cancer compared
with other “peri-ampullary” neoplasms. Current thinking accepts
that an adenoma-dysplasia-carcinoma sequence occurs on either
the intestinal or biliary epithelium overlying the ampulla.25 In6 www.pancreasjournal.comour patient population, subjects with ampullary tumors of the
PB subtype behaved differently in terms of nodal disease burden
and overall survival compared with resections of the intestinal
subtype. Analysis of specimens of the PB subgroup revealed more
advanced nodal disease compared with the intestinal subgroup as
demonstrated by the nodal stage (PB: 34 N2 resections [54.8%] vs
intestinal subtype: 9 N2 resections [23%], P = 0.002). Further-
more, the overall 5-year survival rate of 15.6% in the PB subgroup
was poor and similar to postresectional survival rates for pancre-
atic adenocarcinoma reported elsewhere.26 Differences in tumor
behavior, in terms of recurrence or overall survival, between the
PB and intestinal subgroups have been previously reported by
others.9 We therefore argue that histological subtype is clinically
relevant to patient survival andmay predict biological aggressiveness.
In the UK, the national standard on reporting nodal status in
ampullary cancer as stipulated by the Royal College of Patholo-
gists is based on the presence or absence of metastatic LN (stages
N1 and N0, respectively).24 In 1995, Roder et al18 were the first
to report the prognostic significance of the number of involved
LN in ampullary cancer. In 2014, Kang et al11 proposed, in awell-
defined cohort of patients, a novel substaging system for ampul-
lary cancer based on the number of metastatic nodes. In our study
population, locally advanced disease (N2 ≥3 metastatic LN) was
significantly associated with adverse prognosis; however, it was
not an independent predictor of survival upon multivariate analy-
sis. Previous reports in the literature have highlighted the prognos-
tic value of regional nodal disease either as the absolute number of© 2017 Wolters Kluwer Health, Inc. All rights reserved.
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the anatomical LN location12 on survival in ampullary cancer.
However, the figures reported by each study differed and in some
clear description of what constitutes an ampullary neoplasm is
not easily identifiable. The 2 histological factors (LNR, presence
of vascular invasion) we report independently predict survival and
when used in conjunction can aid clinicians in risk stratifying pa-
tients in terms of prognosis. Inadequate LN retrieval carries an
increased risk of cancer understaging, and recommendations for
minimum number of retrieved nodes after pancreaticoduodenectomy
are in place by various professional bodies (eg, American Joint
Committee in Cancer, UK Royal College of Pathologists).24,27
The validity of the findings we report is strengthened by the me-
dian number of LN examined per specimen (ie, 15 nodes per spec-
imen as per the UK national standards) in our study population.
Patters of recurrence after pancreaticoduodenectomy alone
for ampullary cancer demonstrate that locoregional failure occurs
in up to a third of cases.14,27 However, unlike the case of pancre-
atic cancer, the role of adjuvant chemotherapy for ampullary
cancer is not clear and major work (European Study Group for
Pancreatic Cancer 4 trial) is currently underway. To date, find-
ings on survival benefit from adjuvant chemotherapy or chemo-
radiotherapy are not conclusive due to differing definitions of
ampullary or “periampullary” tumors (study design issues/
retrospective in nature/small sample size) and are therefore sub-
jected to selection bias.23,28–30 Currently, patients with aggressive
disease features such as metastatic LN, positive resectionmargins,
and poorly differentiated tumors are often considered for adju-
vant therapies.23,28–30 The prognostic model we propose, after
adjusting for the chemotherapy regimes that were historically
used in our cohort, is based on highly sensitive statistical analysis
and seems to have higher sensitivity to the currently used nodal
staging classification and is also superior to the substaging system
proposed by Kang et al.11 Hence, we envisage that using the
prognostic model, if further validated prospectively, could help
clinicians to offer adjuvant therapies to those mostly in need until
higher quality evidence is available.
The design of this report is retrospective; hence, bias cannot
be completely eliminated from conclusion. In particular, the impact
of adjuvant chemotherapy on the survival data we report should be
interpreted as it is open to selection bias because the treatment was
not offered as part of a standardized protocol in the 11-year study
period. Nevertheless, the pilot prognostic model we propose is
based on data on a carefully selected patient cohort, and although
it requires validation in a larger patient population, it could aid
clinicians in patient selection for adjuvant therapies in the future.
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